REFERENCES
  1. Vultaggio A, Agache I, A. Akdis C, Akdis M, Bavbek S, Bossios A et al. Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement. Allergy 2020 (in press).
  2. Halpin D, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020 May; 8(5):436-8.
  3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 April; 323(13):1239-42.
  4. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;00:1–12.
  5. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma protective against COVID-19? Allergy 2020;00:1–3.
  6. Zhang JJ, Cao YY, Dong X, Wang BC, Liao MY, Lin J, et al. Distinct characteristics of COVID-19 patients with initial rRt-PCR-positive and rRt-PCR-negative results for SARS-CoV-2. Allergy 2020;00:1–4. 
  7. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven faces of coronavirus disease 2019. Allergy 2020;00:1–11.
  8. Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe outcomes? Allergy 2020 (in press).
  9. Avdeev S, Moiseev S, Brovko M, Yavorovskiy A, Umbetova K, Akulkina L, et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy 2020;00:1–3. 
  10. Plaza V, Fernandez-Rodriguez C, Melero C, Cosio BG, Entrenas LM, de Llano LP, et al. Validation of “Test of the Adherence to Inhalers” (TAI) for asthma and COPD patients. J Aerosol Med Pulm Dug Deliv 2016;29:142-52.
  11. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control test. J Allergy Clin Immunol 2004;113:59-65.
  12. Jordan RE, Adab P, Cheng KK. Covid-19: risk factor for severe disease and death. BMJ 2020;368:m1198.
  13. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146(1):110-8.
  14. Haroun-Díaz E, Vázquez de la Torre M, Ruano FJ, Somoza Álvarez ML, Pérez Alzate D, López González P, et al. Severe asthma during the COVID-19 pandemic: Clinical observations. J Allergy Clin Immunol Pract 2020 (in press).
  15. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. Clin Rev Allergy Immunol. 2020
  16. Gonzales-van Horn SR, Farrar JD. Interferon at the crossroads of allergy and viral infections. J Leukoc Biol. 2015 Aug;98(2):185-94.
  17. Lebre MC, van Capel TM, Bos JD, Knol EF, Kapsenberg ML, de Jong EC. Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients. J Allergy Clin Immunol. 2008;122(5):969‐76.
  18. Richardson PJ, Corbellino M, Stebbing J. Baricitinib for COVID-19: a suitable treatment? -Authors’ reply. Lancet Infect Dis. 2020 Apr 3.
  19. Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007 Aug;81(16):8692-706.
  20. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARSCoV-Infected Mice. Cell Host Microbe. 2016 Feb 10;19(2):181-93.
  21. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig 2020 May; 58(3):155-68.
  22. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv 2020 (in press).
  23. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 2020;202(1):83-90.
  24. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798):270-3.
  25. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79(23):14614-21.
  26. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). Journal of Clinical Medicine 2020;9(3).
  27. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor, ACE2. J Allergy Clin Immunol 2020 jul; 146(1):203-6.
  28. Shi W, Gao Z, Ding Y, Zhu T, Zhang W, Xu Y, et al. Clinical characteristics of COVID-19 patients combined with allergy. Allergy 2020;00:1-4.
  29. Rodrigo-Muñoz JM, Sastre B, Cañas JA, Gil-Martínez M, Redondo N, del Pozo V. Eosinophil Response Against Classical and Emerging Respiratory Viruses: COVID-19. J Investig Allergol Clin Immunol 2021; Vol. 31(2) (in press).
  30. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
  31. Lippi G, Henry BM. Eosinophil count in severe coronavirus disease 2019. QJM 2020 Jul;113(7):511-2.
  32. Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol 2020;146(1):1-7.
  33. Jesenak M, Banovcin P, Diamant Z. COVID-19, chronic inflammatory respiratory diseases and eosinophils – Observations from reported clinical case series. Allergy 2020. (in press).
  34. Riggioni C, Comberiati P, Giovannini M, Agache I, Akdis M, Alves-Correia M, el al. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy 2020. (in press).